Efficacy of glyburide in diabetics poorly controlled on first-generation oral hypoglycemics.
Twenty-four type II (non-insulin-dependent) diabetic patients poorly controlled on maximum doses of first-generation oral hypoglycemic agents were switched to glyburide. There was a significant decrease in glycosylated hemoglobin, but the level was normalized in only four patients; there was no correlation with age, weight, or duration of diabetes. The best predictor for improvement was initial failure on tolbutamide, as opposed to the other first-generation drugs. Patients not controlled with 500 mg/day of chlorpropamide were less likely to benefit from glyburide therapy.
D000284:Administration, Oral; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D002747:Chlorpropamide / Q000008:administration & dosage / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D005905:Glyburide / Q000627:therapeutic use*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D014044:Tolbutamide / Q000008:administration & dosage / Q000627:therapeutic use*
D001786:Blood Glucose; D002747:Chlorpropamide; D005905:Glyburide; D006442:Glycated Hemoglobin; D014044:Tolbutamide